Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
CTC-STOP is a multicentre prospective randomised controlled phase III trial for metastatic castration-resistant prostate cancer patients. This study will determine if serial CTC counts can be used as early markers of progression to direct early discontinuation of docetaxel chemotherapy in patients with mCRPC without adversely impacting overall survival, when compared with standard approaches to guide treatment switch decisions.
Epistemonikos ID: 3b4a630e67c7a79ac4742b8e29cd4327a182b35a
First added on: May 21, 2024